Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwMyeloma 2017 | The biases of using bone marrow biopsies for multiple myeloma

Jens Lohr • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma

A full understanding of the methods available for diagnosis, prognosis and stratification are required in order to choose the optimal method depending on the cirumstances. In this video, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Jens Lohr, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the selection and site bias of using bone marrow biopsies for multiple myeloma. Dr Lohr also questions how representative liquid biopsies are.

More from Jens Lohr

6:28
MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing
Angela Dispenzieri et al. • 10 Sep 2018
10:35
Is MRD testing ready for prime time in myeloma?
Angela Dispenzieri et al. • 10 Sep 2018
3:33
Liquid biopsies for multiple myeloma: the attractions and limits
Jens Lohr • 18 Oct 2017

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals